PT Journal
AU Skarda, J
   Fridman, E
   Plevova, P
   Hajduch, M
   Radova, L
   Ofek, E
   Kopolovic, J
   Kolek, V
   Kolar, Z
TI PROGNOSTIC VALUE OF hMLH1 AND hMSH2 IMMUNOHISTOCHEMICAL EXPRESSION IN NON-SMALL CELL LUNG CANCER. A TISSUE MICROARRAY STUDY
SO Biomedical papers
PY 2006
BP 255
EP 259
VL 150
IS 2
DI 10.5507/bp.2006.037
DE Non-small cell lung cancer/Prognosis/Mismatch repair/hMLH1/ hMSH2/Tissue microarray
AB Background: hMLH1 and hMSH2 genes are both known to play a role in DNA mismatch repair. Nonetheless, the clinical significance of hMLH1 and hMSH2 protein expression in lung cancers remains unclear.Aim: The aim of this study was to investigate the immunohistochemical expression of hMLH1 and hMSH2 proteins in tumor specimens from 179 non-small cell lung cancer (NSCLC) patients using a tissue microarray technique and to correlate these results with other clinicopathological variables, including the disease specific and overall survivals.Method: hMLH1 and hMSH2 protein expression was evaluated by immunohistochemistry using monoclonal antibodies G168-728 for hMLH1 and FE11 for hMSH2 protein expression analysis. The Pearson χ<sup>2</sup> test was used to compare the hMLH1 and hMSH2 alterations among the cases and between various clinical and laboratory variables. P &lt; or = 0.05 was considered statistically significant.Results: Alteration of hMLH1 and hMSH2 protein expression was observed in 10 % of patients. No significant correlation was found between the protein expression and patient age, smoking status, tumor histology or disease stage and disease free and overall survival.Conclusions: Alterations in the expression of hMLH1 and hMSH2 proteins did not have any prognostic value in stage III. NSCLC patients.
ER